Home LiteratureArticle Details
PMID: 19292913 Published · epublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Journal of translational medicine ·Vol. 7 ·2009-03-17 ·Pages 17

Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT

Abstract

The Receptor for Advanced Glycation Endproducts [RAGE] is an evolutionarily recent member of the immunoglobulin super-family, encoded in the Class III region of the major histocompatability complex. RAGE is highly expressed only in the lung at readily measurable levels but increases quickly at sites of inflammation, largely on inflammatory and epithelial cells. It is found either as a membrane-bound or soluble protein that is markedly upregulated by stress in epithelial cells, thereby regulating their metabolism and enhancing their central barrier functionality. Activation and upregulation of RAGE by its ligands leads to enhanced survival. Perpetual signaling through RAGE-induced survival pathways in the setting of limited nutrients or oxygenation results in enhanced autophagy, diminished apoptosis, and (with ATP depletion) necrosis. This results in chronic inflammation and in many instances is the setting in which epithelial malignancies arise. RAGE and its isoforms sit in a pivotal role, regulating metabolism, inflammation, and epithelial survival in the setting of stress. Understanding the molecular structure and function of it and its ligands in the setting of inflammation is critically important in understanding the role of this receptor in tumor biology.

MeSH Terms
Animals High Mobility Group Proteins/metabolism Humans Inflammation/metabolism Ligands Neoplasms/metabolism Receptor for Advanced Glycation End Products Receptors, Immunologic/metabolism S100 Proteins/metabolism
Chemicals
High Mobility Group Proteins Ligands Receptor for Advanced Glycation End Products Receptors, Immunologic S100 Proteins
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Sparvero Louis J
Departments of Surgery and Bioengineering, University of Pittsburgh Cancer Institute, Pittsburgh, USA. [email protected]
Asafu-Adjei Denise
Kang Rui
Tang Daolin
Amin Neilay
Im Jaehyun
Rutledge Ronnye
Lin Brenda
Amoscato Andrew A
Zeh Herbert J
Lotze Michael T
References (191)
191 references, click to expand
  1. Beta amyloid toxicity does not require RAGE protein.
    Biochem Biophys Res Commun. 1997 Aug 8;237(1):37-40 PMID: 9266825
  2. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE).
    J Biol Chem. 2004 Feb 13;279(7):5059-65 PMID: 14617629
  3. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
    Carcinogenesis. 2008 Oct;29(10):2035-43 PMID: 18689872
  4. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.
    Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 PMID: 11390274
  5. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma.
    Ann Surg Oncol. 2009 Feb;16(2):440-6 PMID: 19023628
  6. Brain S100A5 is a novel calcium-, zinc-, and copper ion-binding protein of the EF-hand superfamily.
    J Biol Chem. 2000 Sep 29;275(39):30623-30 PMID: 10882717
  7. Expression, purification and fluorine-18 radiolabeling of recombinant S100 proteins--potential probes for molecular imaging of receptor for advanced glycation endproducts (RAGE) in vivo.
    Protein Expr Purif. 2008 Feb;57(2):143-52 PMID: 18039581
  8. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions.
    Eur J Biochem. 1989 Nov 6;185(2):303-10 PMID: 2583185
  9. Addicted to death: invasive cancer and the immune response to unscheduled cell death.
    J Immunother. 2005 Jan-Feb;28(1):1-9 PMID: 15614039
  10. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA.
    Blood. 2007 Sep 15;110(6):1970-81 PMID: 17548579
  11. Structural interplay between calcium(II) and copper(II) binding to S100A13 protein.
    Angew Chem Int Ed Engl. 2005 Oct 7;44(39):6341-4 PMID: 16145699
  12. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats.
    Neurosci Lett. 2008 Nov 7;445(1):117-21 PMID: 18782604
  13. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene.
    FASEB J. 2009 Jun;23(6):1766-74 PMID: 19164451
  14. Identification, classification, and expression of RAGE gene splice variants.
    FASEB J. 2008 May;22(5):1572-80 PMID: 18089847
  15. The evolution of High Mobility Group Box (HMGB) chromatin proteins in multicellular animals.
    Gene. 2007 Jan 31;387(1-2):133-40 PMID: 17156942
  16. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease.
    Ann N Y Acad Sci. 2008 Apr;1126:147-51 PMID: 18448809
  17. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15.
    J Immunol. 2008 Jul 15;181(2):1499-506 PMID: 18606705
  18. The HMGA proteins: a myriad of functions (Review).
    Int J Oncol. 2008 Feb;32(2):289-305 PMID: 18202751
  19. New insights into the oxidative electrochemistry of vitamin E.
    Acc Chem Res. 2007 Apr;40(4):251-7 PMID: 17269797
  20. Cancer cell metabolism: Warburg and beyond.
    Cell. 2008 Sep 5;134(5):703-7 PMID: 18775299
  21. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes.
    Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1825-30 PMID: 18599803
  22. S100A7 (Psoriasin)--mechanism of antibacterial action in wounds.
    J Invest Dermatol. 2007 Apr;127(4):945-57 PMID: 17159909
  23. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation.
    J Biol Chem. 2000 Dec 22;275(51):40096-105 PMID: 11007787
  24. Calcium-dependent and -independent interactions of the S100 protein family.
    Biochem J. 2006 Jun 1;396(2):201-14 PMID: 16683912
  25. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules.
    J Leukoc Biol. 2007 Jan;81(1):28-37 PMID: 16943388
  26. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.
    Cancer Res. 2002 Aug 15;62(16):4805-11 PMID: 12183440
  27. Calcium-regulated intramembrane proteolysis of the RAGE receptor.
    Biochem Biophys Res Commun. 2008 May 23;370(1):1-5 PMID: 18355449
  28. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs.
    Mod Pathol. 2005 Oct;18(10):1385-96 PMID: 15933755
  29. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.
    J Neurosci. 2008 May 14;28(20):5149-58 PMID: 18480271
  30. Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris.
    Biochem Biophys Res Commun. 2006 Aug 18;347(1):4-11 PMID: 16806067
  31. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Circulation. 2006 Aug 8;114(6):597-605 PMID: 16894049
  32. Binding of Ca2+ and Zn2+ to human nuclear S100A2 and mutant proteins.
    J Biol Chem. 1998 Jul 24;273(30):18826-34 PMID: 9668057
  33. The HMG-1 box protein family: classification and functional relationships.
    Nucleic Acids Res. 1995 May 11;23(9):1604-13 PMID: 7784217
  34. Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction.
    Trends Immunol. 2003 Dec;24(12):622-4 PMID: 14644132
  35. S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses.
    J Neurosci Res. 2006 Apr;83(5):897-906 PMID: 16477616
  36. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis.
    Ann N Y Acad Sci. 2008 Apr;1126:7-13 PMID: 18448789
  37. HMG-1 as a late mediator of endotoxin lethality in mice.
    Science. 1999 Jul 9;285(5425):248-51 PMID: 10398600
  38. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
    J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18 PMID: 17179482
  39. Understanding RAGE, the receptor for advanced glycation end products.
    J Mol Med (Berl). 2005 Nov;83(11):876-86 PMID: 16133426
  40. Discrete proteolytic cleavage of high mobility group proteins.
    Biochem Biophys Res Commun. 1979 Jul 12;89(1):129-33 PMID: 475801
  41. Ancestry and diversity of the HMG box superfamily.
    Nucleic Acids Res. 1993 May 25;21(10):2493-501 PMID: 8506143
  42. Parathymosin affects the binding of linker histone H1 to nucleosomes and remodels chromatin structure.
    J Biol Chem. 2005 Apr 22;280(16):16143-50 PMID: 15716277
  43. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    Angiogenesis. 2008;11(1):91-9 PMID: 18264787
  44. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.
    Cell. 1999 Jun 25;97(7):889-901 PMID: 10399917
  45. N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth.
    J Neurochem. 2002 Mar;80(6):998-1008 PMID: 11953450
  46. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Metabolism. 2006 Sep;55(9):1227-31 PMID: 16919543
  47. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system.
    Nat Med. 2003 Mar;9(3):287-93 PMID: 12598893
  48. S100A13, a new marker of angiogenesis in human astrocytic gliomas.
    J Neurooncol. 2006 Dec;80(3):251-9 PMID: 16773219
  49. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
    Biochem J. 2003 Mar 15;370(Pt 3):1097-109 PMID: 12495433
  50. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix.
    Biochem J. 2008 Dec 1;416(2):255-61 PMID: 18643777
  51. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease.
    J Pept Sci. 2004 May;10(5):229-48 PMID: 15160835
  52. A simple, sensitive and widely applicable ELISA for S100B: Methodological features of the measurement of this glial protein.
    J Neurosci Methods. 2008 Mar 30;169(1):93-9 PMID: 18178255
  53. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells.
    Cell Tissue Res. 2006 Mar;323(3):475-88 PMID: 16315007
  54. Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes.
    Oncogene. 2005 Feb 17;24(8):1445-54 PMID: 15608682
  55. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy.
    Muscle Nerve. 2004 Jun;29(6):853-60 PMID: 15170618
  56. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.
    J Clin Invest. 2004 Dec;114(12):1741-51 PMID: 15599399
  57. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
    Nature. 2000 May 18;405(6784):354-60 PMID: 10830965
  58. The role of the receptor for advanced glycation end-products in lung fibrosis.
    Am J Physiol Lung Cell Mol Physiol. 2007 Dec;293(6):L1427-36 PMID: 17951314
  59. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.
    J Biol Chem. 1992 Jul 25;267(21):14987-97 PMID: 1321822
  60. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response.
    Microbes Infect. 2004 Nov;6(13):1219-25 PMID: 15488742
  61. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma.
    Carcinogenesis. 2005 Feb;26(2):293-301 PMID: 15539404
  62. Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
    J Med Chem. 2003 Nov 20;46(24):5208-21 PMID: 14613323
  63. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation.
    Glycobiology. 2005 Jul;15(7):16R-28R PMID: 15764591
  64. Reversing established sepsis with antagonists of endogenous high-mobility group box 1.
    Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301 PMID: 14695889
  65. In vitro acetylation of HMGB-1 and -2 proteins by CBP: the role of the acidic tail.
    Biochemistry. 2004 Mar 16;43(10):2935-40 PMID: 15005629
  66. Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli.
    J Mol Biol. 1991 Dec 5;222(3):599-620 PMID: 1748995
  67. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.
    J Clin Invest. 2001 Oct;108(7):949-55 PMID: 11581294
  68. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types.
    Am J Respir Cell Mol Biol. 2008 Sep;39(3):337-45 PMID: 18421017
  69. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.
    J Biol Chem. 2007 Oct 26;282(43):31317-31 PMID: 17726019
  70. Molecular cloning and characterization of the human S100A14 gene encoding a novel member of the S100 family.
    Genomics. 2002 Apr;79(4):513-22 PMID: 11944983
  71. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis.
    Acta Neurol Scand. 2009 Aug;120(2):119-22 PMID: 19053950
  72. Posttranslationally modified proteins as mediators of sustained intestinal inflammation.
    Am J Pathol. 2006 Oct;169(4):1223-37 PMID: 17003481
  73. S100 proteins in the epidermis.
    J Invest Dermatol. 2004 Jul;123(1):23-33 PMID: 15191538
  74. A soluble protein characteristic of the nervous system.
    Biochem Biophys Res Commun. 1965 Jun 9;19(6):739-44 PMID: 4953930
  75. Expression and characterization of recombinant C-terminal biotinylated extracellular domain of human receptor for advanced glycation end products (hsRAGE) in Escherichia coli.
    J Biochem. 2008 Feb;143(2):229-36 PMID: 18032414
  76. Biology and physiology of Calbindin-D9k in female reproductive tissues: involvement of steroids and endocrine disruptors.
    Reprod Biol Endocrinol. 2005 Nov 16;3:66 PMID: 16288660
  77. Masquerader: high mobility group box-1 and cancer.
    Clin Cancer Res. 2007 May 15;13(10):2836-48 PMID: 17504981
  78. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.
    Cardiovasc Diabetol. 2007 Mar 07;6:9 PMID: 17343760
  79. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes.
    J Immunol. 2008 Feb 15;180(4):2270-5 PMID: 18250435
  80. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB.
    Diabetes. 2001 Dec;50(12):2792-808 PMID: 11723063
  81. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease.
    Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):147-53 PMID: 17082489
  82. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis.
    Am J Pathol. 2008 Mar;172(3):583-91 PMID: 18245812
  83. Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects.
    J Biol Chem. 2009 Feb 13;284(7):4158-67 PMID: 19073601
  84. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis.
    Nat Clin Pract Rheumatol. 2007 Jul;3(7):382-90 PMID: 17599072
  85. Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies?
    Neurol Res. 2007 Jan;29(1):103-10 PMID: 17427284
  86. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
    Nat Rev Immunol. 2005 Apr;5(4):331-42 PMID: 15803152
  87. Molecular characterization and tissue distribution of a novel member of the S100 family of EF-hand proteins.
    Biochemistry. 2001 Dec 25;40(51):15538-48 PMID: 11747429
  88. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
    Curr Med Chem. 2006;13(17):1971-8 PMID: 16842191
  89. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression.
    Biochem J. 2006 May 15;396(1):109-15 PMID: 16503878
  90. Implications on zinc binding to S100A2.
    Biochim Biophys Acta. 2007 Mar;1773(3):457-70 PMID: 17239974
  91. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.
    J Biol Chem. 1992 Jul 25;267(21):14998-5004 PMID: 1378843
  92. Involvement of the annexin II-S100A10 complex in the formation of E-cadherin-based adherens junctions in Madin-Darby canine kidney cells.
    J Biol Chem. 2005 Feb 18;280(7):6016-27 PMID: 15574423
  93. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
    Mol Med. 2007 Mar-Apr;13(3-4):185-9 PMID: 17592553
  94. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids.
    Eur J Biochem. 1973 Sep 21;38(1):14-9 PMID: 4774120
  95. Parameters for measurement of oxidative stress in diabetes mellitus: applicability of enzyme-linked immunosorbent assay for clinical evaluation.
    J Investig Med. 2005 May;53(4):167-75 PMID: 15974243
  96. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products.
    J Immunol. 2004 Jul 15;173(2):1399-405 PMID: 15240736
  97. An update of the S100 nomenclature.
    Biochim Biophys Acta. 2006 Nov;1763(11):1282-3 PMID: 16938360
  98. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE).
    J Biol Chem. 2008 Oct 3;283(40):27255-69 PMID: 18667420
  99. HMGB1 as a cytokine and therapeutic target.
    J Endotoxin Res. 2002;8(6):469-72 PMID: 12697092
  100. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function.
    J Intern Med. 2004 Mar;255(3):332-43 PMID: 14871457
  101. A review of the S100 proteins in cancer.
    Eur J Surg Oncol. 2008 Apr;34(4):357-64 PMID: 17566693
  102. Structural and functional insights into RAGE activation by multimeric S100B.
    EMBO J. 2007 Aug 22;26(16):3868-78 PMID: 17660747
  103. Construction and characterization of the HMGB1 mutant as a competitive antagonist to HMGB1 induced cytokines release.
    Biochem Biophys Res Commun. 2008 Aug 8;372(4):703-7 PMID: 18515078
  104. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    J Mol Med (Berl). 2009 Mar;87(3):235-47 PMID: 19189073
  105. Binding of S100 proteins to RAGE: an update.
    Biochim Biophys Acta. 2009 Jun;1793(6):993-1007 PMID: 19121341
  106. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes.
    Pathol Biol (Paris). 2006 Sep;54(7):405-19 PMID: 16978799
  107. Architectural regulations and Hmg1.
    Nat Genet. 1999 Jul;22(3):215-7 PMID: 10391203
  108. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Nat Clin Pract Endocrinol Metab. 2008 May;4(5):285-93 PMID: 18332897
  109. RAGE and RAGE ligands in cancer.
    Curr Mol Med. 2007 Dec;7(8):777-89 PMID: 18331236
  110. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.
    J Clin Invest. 2004 Jun;113(11):1641-50 PMID: 15173891
  111. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.
    Nat Med. 2007 Sep;13(9):1042-9 PMID: 17767165
  112. Pathologies involving the S100 proteins and RAGE.
    Subcell Biochem. 2007;45:93-138 PMID: 18193636
  113. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
    Clin Chem. 2006 Jul;52(7):1223-37 PMID: 16644871
  114. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine.
    Ann N Y Acad Sci. 2005 Jun;1043:725-33 PMID: 16037299
  115. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase.
    J Leukoc Biol. 2008 Jul;84(1):292-301 PMID: 18390927
  116. S100A10/p11: family, friends and functions.
    Pflugers Arch. 2008 Jan;455(4):575-82 PMID: 17638009
  117. Does prothymosin-alpha act as molecular switch between apoptosis and autophagy?
    Cell Death Differ. 2003 Sep;10(9):937-9 PMID: 12934067
  118. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family.
    Genomics. 1995 Feb 10;25(3):638-43 PMID: 7759097
  119. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha.
    Neurobiol Aging. 2010 Apr;31(4):665-77 PMID: 18599158
  120. Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes.
    J Immunol. 2008 Jun 15;180(12):8378-85 PMID: 18523305
  121. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.
    Dig Liver Dis. 2008 Jun;40(6):446-52 PMID: 18294942
  122. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment.
    J Exp Med. 2003 Nov 17;198(10):1507-15 PMID: 14623906
  123. V domain of RAGE interacts with AGEs on prostate carcinoma cells.
    Prostate. 2008 May 15;68(7):748-58 PMID: 18302220
  124. Members of the S100 family bind p53 in two distinct ways.
    Protein Sci. 2008 Oct;17(10):1663-70 PMID: 18694925
  125. The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function.
    Vitam Horm. 2003;66:257-96 PMID: 12852257
  126. Mast cell and monocyte recruitment by S100A12 and its hinge domain.
    J Biol Chem. 2008 May 9;283(19):13035-43 PMID: 18292089
  127. RAGE signaling sustains inflammation and promotes tumor development.
    J Exp Med. 2008 Feb 18;205(2):275-85 PMID: 18208974
  128. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling.
    Acta Crystallogr D Biol Crystallogr. 2002 Mar;58(Pt 3):407-13 PMID: 11856825
  129. A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans.
    Nephrol Dial Transplant. 2007 Apr;22(4):1131-5 PMID: 17205963
  130. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail.
    Int J Biochem Cell Biol. 2008;40(8):1536-42 PMID: 18191612
  131. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.
    J Biol Chem. 1995 Oct 27;270(43):25752-61 PMID: 7592757
  132. HMGB4, a novel member of the HMGB family, is preferentially expressed in the mouse testis and localizes to the basal pole of elongating spermatids.
    Biol Reprod. 2009 Feb;80(2):358-66 PMID: 18987332
  133. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.
    Dis Colon Rectum. 2007 Aug;50(8):1230-40 PMID: 17587138
  134. Multiple structural states of S100A12: A key to its functional diversity.
    Microsc Res Tech. 2003 Apr 15;60(6):581-92 PMID: 12645006
  135. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.
    Proc Natl Acad Sci U S A. 1997 May 13;94(10):5296-301 PMID: 9144231
  136. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.
    Curr Mol Med. 2007 Dec;7(8):743-51 PMID: 18331232
  137. FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis.
    J Reprod Immunol. 2005 Oct;67(1-2):87-101 PMID: 16165218
  138. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs).
    J Leukoc Biol. 2002 Mar;71(3):433-44 PMID: 11867681
  139. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2.
    J Clin Invest. 2007 Mar;117(3):693-702 PMID: 17290307
  140. Advanced glycation end-products: a review.
    Diabetologia. 2001 Feb;44(2):129-46 PMID: 11270668
  141. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease.
    J Proteome Res. 2009 Feb;8(2):754-69 PMID: 19093874
  142. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy.
    Eur J Cancer. 2007 Sep;43(13):1935-43 PMID: 17689067
  143. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family.
    Biochem J. 1999 Mar 15;338 ( Pt 3):583-9 PMID: 10051426
  144. S100A16, a novel calcium-binding protein of the EF-hand superfamily.
    J Biol Chem. 2006 Dec 15;281(50):38905-17 PMID: 17030513
  145. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.
    J Clin Invest. 2005 May;115(5):1267-74 PMID: 15841214
  146. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts.
    Mol Nutr Food Res. 2007 Sep;51(9):1111-5 PMID: 17854009
  147. Intracellular and extracellular roles of S100 proteins.
    Microsc Res Tech. 2003 Apr 15;60(6):540-51 PMID: 12645002
  148. Protein glycation, diabetes, and aging.
    Recent Prog Horm Res. 2001;56:1-21 PMID: 11237208
  149. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development.
    Int J Oncol. 2005 Dec;27(6):1473-81 PMID: 16273201
  150. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.
    Shock. 2006 Aug;26(2):174-9 PMID: 16878026
  151. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions.
    J Invest Dermatol. 2004 Feb;122(2):461-7 PMID: 15009731
  152. The extracellular release of HMGB1 during apoptotic cell death.
    Am J Physiol Cell Physiol. 2006 Dec;291(6):C1318-25 PMID: 16855214
  153. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice.
    Nat Genet. 1999 Jul;22(3):276-80 PMID: 10391216
  154. Nitric oxide inhibits the formation of advanced glycation end products.
    Kidney Int. 2000 Oct;58(4):1780-7 PMID: 11012913
  155. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products.
    Arthritis Rheum. 2006 Sep;54(9):2901-11 PMID: 16948116
  156. Assay validation and biological variation of serum receptor for advanced glycation end-products.
    Ann Clin Biochem. 2008 Sep;45(Pt 5):518-9 PMID: 18753428
  157. Statins in tumor suppression.
    Cancer Lett. 2008 Feb 18;260(1-2):11-9 PMID: 18180097
  158. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.
    J Leukoc Biol. 2007 Aug;82(2):204-12 PMID: 17513693
  159. Roles of HMGA proteins in cancer.
    Nat Rev Cancer. 2007 Dec;7(12):899-910 PMID: 18004397
  160. HMG chromosomal proteins in development and disease.
    Trends Cell Biol. 2007 Feb;17(2):72-9 PMID: 17169561
  161. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
    Nature. 2002 Jul 11;418(6894):191-5 PMID: 12110890
  162. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.
    Immunol Rev. 2007 Dec;220:35-46 PMID: 17979838
  163. Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells.
    Cell. 1979 Jan;16(1):181-9 PMID: 369705
  164. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
    Nat Cell Biol. 2006 Dec;8(12):1369-75 PMID: 17128264
  165. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.
    Immunol Rev. 2007 Dec;220:60-81 PMID: 17979840
  166. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products.
    Am J Respir Cell Mol Biol. 2006 Jan;34(1):83-91 PMID: 16166741
  167. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.
    Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7 PMID: 15731496
  168. Folding kinetics of the S100A11 protein dimer studied by time-resolved electrospray mass spectrometry and pulsed hydrogen-deuterium exchange.
    Biochemistry. 2006 Mar 7;45(9):3005-13 PMID: 16503655
  169. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1.
    Mol Immunol. 2005 Feb;42(4):433-44 PMID: 15607795
  170. Hypoxia, glucose metabolism and the Warburg's effect.
    J Bioenerg Biomembr. 2007 Jun;39(3):223-9 PMID: 17661163
  171. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins.
    Curr Mol Med. 2007 Dec;7(8):711-24 PMID: 18331229
  172. RAGE ligation affects T cell activation and controls T cell differentiation.
    J Immunol. 2008 Sep 15;181(6):4272-8 PMID: 18768885
  173. Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration.
    J Neurochem. 2004 Sep;90(6):1389-401 PMID: 15341523
  174. HMG1 proteins from evolutionary distant organisms distort B-DNA conformation in similar way.
    Biochim Biophys Acta. 1999 Oct 6;1447(1):25-34 PMID: 10500240
  175. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Microvasc Res. 2008 May;76(1):52-6 PMID: 18474381
  176. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
    FASEB J. 2008 Oct;22(10):3716-27 PMID: 18603587
  177. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches.
    J Biol Chem. 2007 Feb 9;282(6):4218-31 PMID: 17158877
  178. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.
    J Leukoc Biol. 2008 Jun;83(6):1484-92 PMID: 18339893
  179. The calcium-binding protein S100P in normal and malignant human tissues.
    BMC Clin Pathol. 2008 Feb 18;8:2 PMID: 18282279
  180. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases.
    J Biol Chem. 2008 Dec 19;283(51):35507-16 PMID: 18952609
  181. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE).
    J Biol Chem. 2004 Nov 26;279(48):50019-24 PMID: 15381690
  182. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1.
    J Leukoc Biol. 2007 Mar;81(3):741-7 PMID: 17135572
  183. Large scale isolation and purification of soluble RAGE from lung tissue.
    Protein Expr Purif. 2008 Sep;61(1):99-101 PMID: 18558495
  184. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1.
    Arthritis Rheum. 2006 Dec;54(12):3898-907 PMID: 17133598
  185. S100A11, an dual mediator for growth regulation of human keratinocytes.
    Mol Biol Cell. 2008 Jan;19(1):78-85 PMID: 17978094
  186. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.
    Arterioscler Thromb. 1994 Oct;14(10):1521-8 PMID: 7918300
  187. Biological and methodological features of the measurement of S100B, a putative marker of brain injury.
    Clin Biochem. 2008 Jul;41(10-11):755-63 PMID: 18454941
  188. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.
    J Biol Chem. 2006 Mar 24;281(12):8242-53 PMID: 16407300
  189. Mapping intramolecular interactions between domains in HMGB1 using a tail-truncation approach.
    J Mol Biol. 2007 Dec 14;374(5):1286-97 PMID: 17988686
  190. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42.
    J Biol Chem. 2008 Dec 5;283(49):34457-68 PMID: 18922799
  191. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.
    EMBO J. 2003 Oct 15;22(20):5551-60 PMID: 14532127
Article Info
Journal
Journal of translational medicine
Abbr.
J Transl Med
ISSN
1479-5876
Published
2009-03-17
Epub
2009-00-17
Pages
17
Language
English
Region
England
NLM ID
101190741
PMCID
PMC2666642
Subset
IM
Grants
NCI NIH HHS · P01 CA101944 · United States
NCI NIH HHS · 1 PO1 CA 101944-01A2 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]